GlassScriptPhysician profile
Pedro Yen
NPI 1720163751
$5,211.16
in general payments reported to CMS, 2019-2025
23 companies · $832 in 2025
The $832 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $887 · 2020: $79.68 · 2021: $636 · 2022: $218 · 2023: $970 · 2024: $1,588 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,091 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,090.50 |
| Education | $299.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,490.67 | 2021-2025 | Airsupra, Farxiga, Bydureon |
| Abbott Laboratories | $712.80 | 2022-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $648.23 | 2019-2024 | Bexsero, Arexvy, Shingrix |
| Amgen INC. | $566.58 | 2021-2023 | Repatha, Otezla |
| Pfizer INC. | $286.56 | 2019-2025 | |
| Sanofi Pasteur INC. | $284.36 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $272.78 | 2019 | |
| Optinose US, INC. | $149.19 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $133.77 | 2019 | |
| Gilead Sciences, INC. | $113.63 | 2019 | |
| Novo Nordisk As | $82.05 | 2023 | |
| Ani Pharmaceuticals, INC. | $78.28 | 2024 | Purified Cortrophin Gel |
| Xeris Pharmaceuticals, INC. | $69.19 | 2022-2023 | Keveyis |
| Lilly USA, LLC | $67.39 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Exact Sciences Corporation | $65.69 | 2024-2025 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $42.03 | 2025 | Korlym |
| Genentech USA, INC. | $29.73 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $27.99 | 2025 | Zoryve |
| Abbvie INC. | $26.25 | 2021-2023 | Qulipta |
| Phadia US INC. | $19.55 | 2024 | Immunocap |
| Novo Nordisk INC | $16.67 | 2022 | |
| Cranial Technologies, INC | $14.70 | 2025 | Doc Band |
| Steris Corporation | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedro Yen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.